Search

Your search keyword '"Friis, Lone S"' showing total 28 results
Start Over Author "Friis, Lone S"
28 results on '"Friis, Lone S"'

2. Pulmonary function is a strong predictor of 2-year overall survival and non-relapse mortality after allogenic hematopoietic cell transplantation

Author

Schierbeck, Frederikke, Mortensen, Jann, Andersen, Niels S., Friis, Lone S., Kornblit, Brian, Petersen, Søren L., Schjødt, Ida, Sengeløv, Henrik, Schierbeck, Frederikke, Mortensen, Jann, Andersen, Niels S., Friis, Lone S., Kornblit, Brian, Petersen, Søren L., Schjødt, Ida, and Sengeløv, Henrik

Abstract

Objectives: The purpose of the study was to assess the validity of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and of pulmonary comorbidity prior to HCT in terms of predicting non-relapse mortality (NRM) and overall survival (OS). Methods: In this retrospective single-center study of 663 consecutive adult recipients of HCT, we stratified patients into groups by pulmonary comorbidity: low-risk, intermediate-risk, and high-risk. The predictive value of this pulmonary comorbidity score (PCS) was compared to HCT-CI. Results: In univariate analysis, the HCT-CI and the PCS were associated with OS after transplantation when comparing patients in high-risk groups with patients in low-risk groups. Using the PCS, the hazard ratios (HRs) of the 2-year OS in the entire population and in the myeloablative conditioning (MAC) group were 1.98 (p <.001) and 3.27 (p <.001), respectively, whereas the HRs using the HCT-CI were 1.83 (p <.001) and 2.57 (p =.002). The 2-year NRM incidence in the three risk-groups in the entire population was significant using both indexes. In the MAC group, the 2-year NRM was significant using the PCS (p =.003), but not using the HCT-CI (p =.23). Conclusions: Our study suggest that pulmonary function alone is a strong predictor of 2-year OS and NRM after HCT.

Published
2023

3. Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020:A Danish population-based cohort study

Author

Gjærde, Lars K., Jakobsen, Lasse H, Juhl-Christensen, Caroline, Olesen, Gitte, Petruskevicius, Irma, Severinsen, Marianne T, Marcher, Claus W, Theilgaard-Mönch, Kim, Andersen, Niels S, Friis, Lone S, Kornblit, Brian, Petersen, Søren L, Schjødt, Ida, Sengeløv, Henrik, Gjærde, Lars K., Jakobsen, Lasse H, Juhl-Christensen, Caroline, Olesen, Gitte, Petruskevicius, Irma, Severinsen, Marianne T, Marcher, Claus W, Theilgaard-Mönch, Kim, Andersen, Niels S, Friis, Lone S, Kornblit, Brian, Petersen, Søren L, Schjødt, Ida, and Sengeløv, Henrik

Published
2023

5. Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population‐based cohort study

Author

Gjærde, Lars K., primary, Jakobsen, Lasse H., additional, Juhl‐Christensen, Caroline, additional, Olesen, Gitte, additional, Petruskevicius, Irma, additional, Severinsen, Marianne T., additional, Marcher, Claus W., additional, Theilgaard‐Mönch, Kim, additional, Andersen, Niels S., additional, Friis, Lone S., additional, Kornblit, Brian, additional, Petersen, Søren L., additional, Schjødt, Ida, additional, and Sengeløv, Henrik, additional

Published
2022
Full Text
View/download PDF

6. Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population‐based cohort study.

Author

Gjærde, Lars K., Jakobsen, Lasse H., Juhl‐Christensen, Caroline, Olesen, Gitte, Petruskevicius, Irma, Severinsen, Marianne T., Marcher, Claus W., Theilgaard‐Mönch, Kim, Andersen, Niels S., Friis, Lone S., Kornblit, Brian, Petersen, Søren L., Schjødt, Ida, and Sengeløv, Henrik

Subjects
ACUTE myeloid leukemia, CELL transplantation, COHORT analysis, HEMATOPOIETIC stem cell transplantation, CORD blood
Published
2023
Full Text
View/download PDF

10. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

Author

Gagelmann, Nico, primary, Eikema, Diderik-Jan, additional, Stelljes, Matthias, additional, Beelen, Dietrich, additional, de Wreede, Liesbeth, additional, Mufti, Ghulam, additional, Knelange, Nina Simone, additional, Niederwieser, Dietger, additional, Friis, Lone S., additional, Ehninger, Gerhard, additional, Nagler, Arnon, additional, Yakoub-Agha, Ibrahim, additional, Meijer, Ellen, additional, Ljungman, Per, additional, Maertens, Johan, additional, Kanz, Lothar, additional, Lopez-Corral, Lucia, additional, Brecht, Arne, additional, Craddock, Charles, additional, Finke, Jürgen, additional, Cornelissen, Jan J., additional, Bernasconi, Paolo, additional, Chevallier, Patrice, additional, Sierra, Jorge, additional, Robin, Marie, additional, and Kröger, Nicolaus, additional

Published
2019
Full Text
View/download PDF

11. Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma

Author

Fridthjof, Katrine S., primary, Kampmann, Peter, additional, Dünweber, Anne, additional, Gørløv, Jette S., additional, Nexø, Connie, additional, Friis, Lone S., additional, Nørskov, Kristina H., additional, Welinder, Pernille C., additional, Moser, Claus, additional, Kjeldsen, Lars, additional, and Møller, Tom, additional

Published
2018
Full Text
View/download PDF

14. Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma

Author

Fridthjof, Katrine S, Kampmann, Peter, Dünweber, Anne, Gørløv, Jette S, Nexø, Connie, Friis, Lone S, Nørskov, Kristina H, Welinder, Pernille C, Moser, Claus, Kjeldsen, Lars, Møller, Tom, Fridthjof, Katrine S, Kampmann, Peter, Dünweber, Anne, Gørløv, Jette S, Nexø, Connie, Friis, Lone S, Nørskov, Kristina H, Welinder, Pernille C, Moser, Claus, Kjeldsen, Lars, and Møller, Tom

Abstract

Based on experience with comprehensive patient involvement, we present data from implementation of portable, programmable infusion pumps (PPP) for home-based chemotherapy administration in patients with acute leukaemia and in lymphoma patients receiving (carmustine, etoposide, cytarabine, melphalan) BEAM regimen. Data from 84 patients, receiving 177 cycles of PPP administered chemotherapy, showed convincing safety with minor equipment errors encountered and with high patient satisfaction. In-hospital days could be reduced with 52% out of a total of 1197 treatment days. Homebased PPP has several advantages from a patient perspective and furthermore frees up in-hospital beds for patients in need of them.

Published
2018

15. Addressing the room for improvement in management of acute promyelocytic leukemia.

Author

Nørgaard, Jan M., Mølle, Ingolf, Kjeldsen, Eigil, Østgård, Lene S.G., Kristensen, Jørgen S., Medeiros, Bruno C., Friis, Lone S., Nielsen, Ove J., Severinsen, Marianne T., Marcher, Claus W., Møller, Peter, Schoellkopf, Claudia, Preiss, Birgitte S., and Andersen, Mette K.

Subjects
ACUTE promyelocytic leukemia, DISSEMINATED intravascular coagulation, ACUTE leukemia, MULTIPLE organ failure, EARLY death, THERAPEUTICS, DEATH rate
Abstract

Acute promyelocytic leukemia (APL) is highly curable. To achieve high cure rates, targeted therapy with retinoic acid (ATRA) must be started promptly at time of suspected diagnosis. Early death rates (EDRs, ≤30 days from diagnosis) differ markedly in patients treated on clinical trials compared to the general population. Objectives and methods: We used the comprehensive Danish National Acute Leukemia Registry (DNLR) to investigate the incidence, treatment, EDR, and long‐term clinical outcome in APL between 2000 and 2014. Results: Twenty‐two of 41 deaths occurring in 122 APL patients were EDs which were primarily caused by intracranial hemorrhage, disseminated intravascular coagulation (DIC), sepsis, and multiorgan failure. The overall EDR was 18.0%, whereas clinical trial participants had an EDR of 6.7%. Fifteen patients recruited to the NCRI AML17 APL trial from 2010 to 2013 were younger and had decreased mortality (HR 0.18, CI 0.04‐0.86, P = 0.02) compared to contemporarily treated patients (n = 15) not recruited to a clinical trial. Performance status, leukemia origin, and Sanz‐score were independent prognostic variables. Conclusions: The very low EDR for on‐trial patients is not observed in the general cohort of APL patients. Diagnostic awareness emerges as the greatest clinical challenge in management of APL. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

22. Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Author

Treppendahl, Marianne B., primary, Tobiasson, Magnus, additional, Aggerholm, Anni, additional, Karimi, Mohsen, additional, Silkjaer, Trine, additional, Friis, Lone S., additional, Andersen, Mette K., additional, Kjeldsen, Lars, additional, Holm, Mette S., additional, Hellström-Lindberg, Eva, additional, and Grønbæk, Kirsten, additional

Published
2012
Full Text
View/download PDF

23. High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study

Author

Norgaard, Jan M., primary, Ostgard, Lene Sofie Granfeldt, additional, Kjeldsen, Eigil, additional, Holm, Mette S., additional, Kjeldsen, Lars, additional, Kallenbach, Maria, additional, Severinsen, Marianne T., additional, Johansen, Preben, additional, Friis, Lone S., additional, Weber, Duruta, additional, Kerndrup, Gitte, additional, Preiss, Birgitte, additional, Jensen, Morten K., additional, Dufva, Inge H., additional, Timshel, Susanne, additional, Andersen, Mette K., additional, and Nielsen, Ove J., additional

Published
2012
Full Text
View/download PDF

24. Extramedullary Leukemia and Myeloid Sarcoma in AML: Results From a Population-Based Registry Study of 2261 Patients

Author

Oestgaard, Lene S.G., primary, Sengeloev, Henrik, additional, Holm, Mette S., additional, Johnsen, Hans E., additional, Severinsen, Marianne T., additional, Kjeldsen, Eigil, additional, Bergmann, Olav J., additional, Friis, Lone S., additional, Jensen, Morten K., additional, Nielsen, Ove J., additional, Kjeldsen, Lars, additional, and Norgaard, Jan M., additional

Published
2011
Full Text
View/download PDF

25. Trends in hematological cancer in the elderly in Denmark, 1980–2012.

Author

Ocias, Lukas F., Larsen, Thomas S., Vestergaard, Hanne, Friis, Lone S., Abildgaard, Niels, and Frederiksen, Henrik

Subjects
AGE distribution, CHRONIC lymphocytic leukemia, LYMPHOMAS, MULTIPLE myeloma, SURVIVAL, ACUTE myeloid leukemia, DISEASE incidence, DISEASE prevalence, HEMATOLOGIC malignancies, OLD age, DIAGNOSIS
Abstract

BackgroundThe number of hematological malignancies is expected to increase as the Danish population ages within the next few decades. Despite this, data on the course of hematological cancers among the oldest patients are sparse with many intervention studies focusing on younger age groups. The aim of this study is to present Danish incidence and mortality rates among older patients with non-Hodgkin lymphomas (NHL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). Material and methodsNationwide population-based study presenting the incidence, prevalence and mortality rates of NHL, MM, and AML with a focus on the elderly population in Denmark during the last few decades. Data were drawn from the NORDCAN database. ResultsIncidence rates of NHL, MM, CLL and AML were 10–50 times higher among the population aged 70 years or more than among the younger population. An increasing incidence with stable or decreased mortality rates was seen mainly among elderly patients with NHL during the last few decades, leading to increased survival and a greater prevalence of patients with NHL. Increased relative survival and prevalence could also be seen among elderly patients with MM and CLL, while the trends of the incidence rates were inconclusive for these diseases. Survival among patients with AML improved most notably in those aged below 70 years leading to an increased prevalence of AML patients predominantly in this age group. ConclusionImprovements in diagnostics and treatment have led to increased survival and therefore prevalence of elderly patients with NHL, MM, CLL and AML during the past decades. [ABSTRACT FROM PUBLISHER]

Published
2016
Full Text
View/download PDF

28. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.

Author

Ørskov AD, Treppendahl MB, Skovbo A, Holm MS, Friis LS, Hokland M, and Grønbæk K

Subjects
Aged, Aged, 80 and over, Blood Cells drug effects, Blood Cells metabolism, Drug Resistance, Female, Gene Expression Regulation drug effects, Humans, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute metabolism, Leukemia, Myelomonocytic, Chronic drug therapy, Leukemia, Myelomonocytic, Chronic genetics, Leukemia, Myelomonocytic, Chronic metabolism, Lymphocyte Activation, Male, Middle Aged, Myelodysplastic Syndromes genetics, Myelodysplastic Syndromes metabolism, Neoplasm Proteins biosynthesis, Neoplasm Proteins genetics, Neoplasm Proteins physiology, Programmed Cell Death 1 Receptor biosynthesis, Programmed Cell Death 1 Receptor physiology, Promoter Regions, Genetic drug effects, RNA, Messenger biosynthesis, RNA, Messenger genetics, RNA, Neoplasm biosynthesis, RNA, Neoplasm genetics, T-Lymphocyte Subsets drug effects, Antimetabolites pharmacology, Azacitidine pharmacology, DNA Methylation drug effects, Myelodysplastic Syndromes drug therapy, Programmed Cell Death 1 Receptor genetics, Promoter Regions, Genetic genetics, T-Lymphocyte Subsets metabolism
Abstract

The hypomethylating agents (HMAs) are standard therapy for patients with higher-risk myelodysplastic syndrome (MDS); however, the majority of the patients will lose their response to HMAs over time due to unknown mechanisms. It has recently been shown that T cell expression of the immunoinhibitory receptor PD-1 is regulated by DNA methylation. In 12 of 27 patients (44%) PD-1 promoter demethylation was observed in sorted peripheral blood T cells isolated over consecutive cycles of treatment with 5-azacytidine (5-aza). The PD-1 promoter demethylation correlated with an increase in PD-1 expression. Moreover, demethylation of the PD-1 promoter correlated with a significantly worse overall response rate (8% vs. 60%, p = 0.014), and a trend towards a shorter overall survival (p = 0.11) was observed. A significantly higher baseline methylation level of the PD-1 promoter was observed in T cells of non-responding patients compared to healthy controls (p = 0.023). Accordingly, in addition to their beneficial function, HMAs induce PD-1 expression on T cells in the MDS microenvironment, thereby likely hampering the immune response against the MDS blasts. Thus, we suggest that activation of the PD-1 checkpoint during HMA treatment can be a possible resistance mechanism, which may be overcome by combination therapy with a PD-1 pathway inhibitor.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results